JPRN-UMIN000051278Completed未知
Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan - Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan
Kimitsu Chuo Hospital0 sites356,266 target enrollmentStarted: June 7, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 356,266
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •the patients under 20 years old, treated without anti-diabetic drugs, not treated new drugs during observation period, with cancer, or undergoing dialysis treatment.
Investigators
Similar Trials
Not yet recruiting
Phase 2
SemaPsychiatrySchizophrenia2024-518746-24-00Psykiatrisk Center Kobenhavn104
Completed
Not Applicable
The influence of GLP-1 receptor agonist on the heart rate using holter electrocardiography and power spectrum analysis on heart rate variabilityType 2 diabetesJPRN-UMIN000017770Dokkyomedical university nikko medical center50
Active, not recruiting
Phase 1
Does stimulation of the receptor for Glucagon-like Peptide 1 (GLP-1) reduce alcohol intake in patients with alcohol dependence?Alcohol dependenceEUCTR2016-003343-11-DKPsychiatric Centre Copenhagen169
Active, not recruiting
Phase 1
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
Completed
Phase 1
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24